Literature DB >> 28447980

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals.

Phillip G Durham1, Shumaila N Hanif2, Lucia Garcia Contreras2, Ellen F Young3, Miriam S Braunstein3, Anthony J Hickey4.   

Abstract

Development of new therapeutic products requires efficacy testing in an animal model. The pulmonary route of administration can be utilized to deliver drugs locally and systemically. Evaluation of dry powder aerosols necessitates an efficient dispersion mechanism to maintain high concentrations in an exposure chamber or for direct endotracheal administration. While solutions exist to expose animals by passive inhalation to dry powder aerosols, most require masses of powder in large excess of the dose delivered. This precludes conducting early feasibility studies as insufficient drug is available at the research or early development stage to support the dose delivery requirements for conventional aerosol delivery systems. When designing an aerosol drug product, aerodynamic performance can relate directly to delivery efficiency and efficacy. Dispersion of powder into an aerosol requires energy input sufficient to overcome interparticulate forces, and particle engineering approaches can substantially improve aerosol performance. We have developed a dispersion system (dosator) which can aerosolize engineered dry powder aerosols efficiently for the purpose of direct pulmonary insufflation, dispersion into an exposure system or generation for analytical purposes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28447980      PMCID: PMC5564432          DOI: 10.3791/55356

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  10 in total

Review 1.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

Review 2.  Dry powder aerosol delivery systems: current and future research directions.

Authors:  Hak-Kim Chan
Journal:  J Aerosol Med       Date:  2006

3.  Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.

Authors:  Jean C Sung; Lucila Garcia-Contreras; Jarod L Verberkmoes; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

4.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

Review 5.  Dry powder inhalers (DPIs)--a review of device reliability and innovation.

Authors:  Nazrul Islam; Ellen Gladki
Journal:  Int J Pharm       Date:  2008-05-09       Impact factor: 5.875

6.  Pulmonary delivery of dry powders to rats: tolerability limits of an intra-tracheal administration model.

Authors:  A Guillon; J Montharu; L Vecellio; V Schubnel; G Roseau; J Guillemain; P Diot; M de Monte
Journal:  Int J Pharm       Date:  2012-05-15       Impact factor: 5.875

7.  Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.

Authors:  C Bosquillon; C Lombry; V Préat; R Vanbever
Journal:  J Control Release       Date:  2001-02-23       Impact factor: 9.776

8.  Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected].

Authors:  P G Durham; Y Zhang; N German; N Mortensen; J Dhillon; D A Mitchison; P B Fourie; A J Hickey
Journal:  Mol Pharm       Date:  2015-07-01       Impact factor: 4.939

9.  Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies.

Authors:  Melissa Morello; Cassandra L Krone; Shelley Dickerson; Elizabeth Howerth; Willem Andreas Germishuizen; Yun-Ling Wong; David Edwards; Barry R Bloom; Mary K Hondalus
Journal:  Tuberculosis (Edinb)       Date:  2009-07-26       Impact factor: 3.131

10.  Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Authors:  L Garcia-Contreras; J Fiegel; M J Telko; K Elbert; A Hawi; M Thomas; J VerBerkmoes; W A Germishuizen; P B Fourie; A J Hickey; D Edwards
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

  10 in total
  2 in total

1.  Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.

Authors:  Ian E Stewart; Pradeep B Lukka; Jiuyu Liu; Bernd Meibohm; Mercedes Gonzalez-Juarrero; Miriam S Braunstein; Richard E Lee; Anthony J Hickey
Journal:  Pharm Res       Date:  2019-07-18       Impact factor: 4.200

2.  Performance of Low Air Volume Dry Powder Inhalers (LV-DPI) when Aerosolizing Excipient Enhanced Growth (EEG) Surfactant Powder Formulations.

Authors:  Susan Boc; Mohammad A M Momin; Dale R Farkas; Worth Longest; Michael Hindle
Journal:  AAPS PharmSciTech       Date:  2021-04-15       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.